The FDA recently approved Shield, a blood test by Guardant Health, for screening colorectal cancer in individuals aged 45+

 with an “average risk.” While not a substitute for colonoscopies, Shield aims to enhance accessibility and insurance coverage,

potentially increasing screening rates due to its convenience. The test, with a 10% false positive rate and a 13% detection rate of large polyps, offers results in about two weeks by analyzing DNA from tumor shed in blood samples. This approval marks a significant step towards early detection and prevention of colorectal cancer, providing a non-invasive screening option for those at average risk. Learn more about Shield and its impact on colorectal cancer screening.

Source ABC News